Compounded GLP-1 injections made by a pharmacy that the Food and Drug Administration previously warned was putting "patients at risk" have been recalled nationwide — a story trending per news coverage as millions of weight-loss drug users check whether their vials are affected.
Apothecary Pharma LLC first initiated a voluntary recall of tirzepatide injections — the active ingredient in Eli Lilly's Zepbound and Mounjaro — on September 24, citing a "lack of assurance of sterility," according to an FDA enforcement notice. The federal agency updated the recall on October 10, classifying it as a "Class II" recall, which means using the medication could cause "temporary or medically reversible adverse health consequences," though the risk of serious harm is considered small.
Which compounded GLP-1 injections were recalled?
The recall covers 22 lots of compounded tirzepatide injection — 18 mg/mL in a 4 mL sterile multi-dose vial, NDC 85091-001-18, prescription-only — distributed nationwide. The recalled lots are AP-202622 through AP-202625 and AP-202627 through AP-202644, with beyond-use dates ranging from October 7 to November 26, 2026. One lot of NAD+ injection (200 mg/mL, 6 mL multidose vial, lot AP-202647, beyond-use date October 13, 2026) was also recalled.
Crucially, these are compounded versions of the drug — not name-brand, FDA-approved Zepbound or Mounjaro. A compounding pharmacy custom-formulates medications from raw ingredients to meet a patient's specific needs, such as adjusting a dose or removing an allergen like a dye. Unlike a commercial pharmacy selling mass-produced drugs, a compounder's formulations are not individually evaluated for purity, safety or effectiveness, and compounding pharmacies are not routinely inspected by the FDA — a gap that has produced sanitation and contamination scandals in the past.
The 2012 fungal meningitis precedent
Sterility failures in compounding pharmacies have a grim history. In 2012, nearly 800 people became ill and 64 died in a fungal meningitis outbreak traced to unsanitary steroid injections from the New England Compounding Center in Massachusetts — the deadliest pharmaceutical contamination disaster in modern US history. That tragedy led to the Drug Quality and Security Act of 2013, which created a new category of registered "outsourcing facilities" subject to stricter FDA oversight.
Apothecary Pharma is not registered as an outsourcing facility. In December 2025, the FDA sent the North Carolina company a warning letter listing several violations, including "serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk." The agency has not publicly established a connection between those findings and the current recall, and no illnesses or injuries linked to the recalled lots have been reported, according to the FDA notice.
Why compounded GLP-1s are under the FDA's microscope
Compounded GLP-1s became a special focus of the FDA after tirzepatide and semaglutide were removed from the official drug shortage list in late 2024 and early 2025. During the shortage years beginning in 2022, the FDA gave compounders the go-ahead to produce their own versions of the weight-loss drugs in bulk to fill the void — a legal but temporary exception that let telehealth platforms and wellness clinics sell millions of doses at a fraction of the brand-name price.
Once the shortage ended, compounders were expected to stop producing the copies en masse. Many continued anyway, prompting the agency to issue warnings, send cease-and-desist pressure, and face a wave of legal challenges — with drugmakers Eli Lilly and Novo Nordisk suing compounders to stop or limit the practice. Wegovy and Zepbound are usually more expensive than the compounded versions, and fewer than half of large US employer health insurance plans cover the drugs when prescribed for weight loss — the price gap that keeps patients buying the compounded copies.
What patients should do
The FDA and Apothecary Pharma have not issued a public statement clarifying what patients should do with affected vials, leaving affected users in limbo. USA Today contacted Apothecary Pharma and the FDA for comment on October 19 but had not received a response. Customers online have reported receiving requests through their prescribers to return or dispose of the vials, or to contact the manufacturer directly.
NewLife Rx, a pharmaceutical fulfillment service that distributed some of the recalled vials, told customers — relaying what Apothecary told its team — that the recall was a documentation issue and that it was on a "retail level, which does not extend to patients or require them to stop using or return their medications," according to a notice reviewed by USA Today. Neither the FDA nor Apothecary has publicly confirmed that characterization, however. While Class II recalls generally mean a product can often continue to be used without major health risks unless otherwise stated, the classification does not mean there are no risks at all.
If you have an affected lot, do not use it without first consulting your prescriber or healthcare provider for instructions. Check the lot number printed on your vial against the FDA's recall list, contact your pharmacist or prescriber, and seek medical advice if you experience fever, redness, swelling or worsening pain after an affected injection — the same red-flag symptoms doctors cite for any potentially contaminated injectable. To check whether your compounding pharmacy is reputable, the Alliance for Pharmacy Compounding maintains a public member directory — and always discuss alternatives with your doctor before switching products, as recalls, like the recent Kayem Foods recall, show why verifying the product you hold matters.
What happens next
The recall remains ongoing: Apothecary initiated it on September 24 and notified recipients by letter, and the FDA's Class II classification stands. The episode adds to the regulatory pressure on the compounded GLP-1 industry — an industry serving millions of patients caught between brand-name prices and uncertain insurance coverage. Whether the FDA takes further enforcement action against Apothecary Pharma, and whether other compounders face similar sterility findings, will determine how this recall is remembered: as an isolated documentation lapse, or as the first crack in a much bigger post-shortage reckoning. For now, patients on compounded tirzepatide face an uncomfortable choice — trust the retail-level reassurance relayed through their fulfillment services, or wait for the clearer public statement that the FDA and the company have so far declined to give.